https://allsci.com/news/regulatory/fda-clinical-hold-opakalim-partial-on-biohavens/ AllScien 2026-09-10T17:50:09.630019Z FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track https://allsci.com/news/funding/neonc-funding-cns-cancer-raises-usd-15m-to/ AllScien 2026-09-10T17:39:26.601356Z NeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout https://allsci.com/news/clinical-trials/atogepant-menstrual-migraine-abbvies-meets/ AllScien 2026-09-10T15:45:20.115410Z AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial https://allsci.com/news/venture-financing/spinal-cord-injury-genetic-medicine-vianautis/ AllScien 2026-09-10T15:23:01.290558Z ViaNautis expands into spinal cord injury with SCI Ventures backing for polyNaut platform https://allsci.com/news/clinical-trials/ruvonoflast-phase-ii-trial-rezeras-cuts/ AllScien 2026-09-10T15:09:59.570699Z NodThera rebrands as Rezera as ruvonoflast meets Phase II endpoint, eyes Phase III in PAD https://allsci.com/news/research/quinacrine-cutaneous-lupus-treatment-mindera/ AllScien 2026-09-10T14:50:23.280930Z Mindera Health partners with UPenn to investigate quinacrine mechanism in lupus https://allsci.com/news/clinical-trials/istaroxime-cardiogenic-shock-trial-seismic/ AllScien 2026-09-10T10:45:11.062233Z Seismic launches global Phase III trial of istaroxime in cardiogenic shock https://allsci.com/news/grants/heart-failure-ai-system-updoc-receives-up-to-92/ AllScien 2026-09-10T10:35:28.951396Z UpDoc receives up to USD 9.2m from ARPA-H for autonomous heart failure AI system https://allsci.com/news/funding/a2m-osteoarthritis-clinical-trial-cytonics-raises/ AllScien 2026-09-10T10:27:14.260338Z Cytonics crowdfunds USD 4.8m to advance A2M biologic into Phase Ib/IIa osteoarthritis study https://allsci.com/news/development/focused-ultrasound-brain-drug-delivery-lotus/ AllScien 2026-09-10T10:20:09.456550Z Insightec spinout Lotus Neuro launches brain drug delivery platform https://allsci.com/news/clinical-trials/polycythemia-vera-treatment-disc-medicines/ AllScien 2026-09-10T10:14:14.629174Z Disc Medicine’s DISC-3405 reduces phlebotomy needs in Phase II polycythemia vera trial https://allsci.com/news/clinical-trials/ai-drug-phase-iii-ipf-trial-insilico-advances/ AllScien 2026-09-10T09:51:43.145571Z Insilico’s rentosertib becomes first AI-discovered drug to enter Phase III https://allsci.com/news/grants/heart-failure-ai-agent-tempus-secures-95-million/ AllScien 2026-09-10T09:46:08.210307Z Tempus wins USD 9.5m in ARPA-H funding to develop autonomous cardiology AI https://allsci.com/news/regulatory/enspryng-mogad-fda-approval-grants-priority/ AllScien 2026-09-10T09:33:07.227624Z Roche moves Enspryng toward first approved MOGAD therapy https://allsci.com/news/approvals/her2-mutated-lung-cancer-treatment-fda-grants/ AllScien 2026-09-10T09:11:19.843253Z Bayer’s Hyrnuo joins Boehringer’s Hernexeos in first-line HER2-mutant NSCLC https://allsci.com/news/research/prmt7-cd8-t-cell-mcgill-and-mount-sinai/ AllScien 2026-09-10T07:58:52.461711Z McGill and Mount Sinai researchers identify PRMT7 as suppressor of CD8+ T cell expansion https://allsci.com/news/clinical-trials/biontech-trial-termination-colorectal-cancer/ AllScien 2026-09-09T17:17:44.398676Z BioNTech ends autogene cevumeran Phase II after OS imbalance favors control https://allsci.com/news/licensing-and-partnerships/parp1-inhibitor-license-asia-lees-pharm-licenses/ AllScien 2026-09-09T17:13:07.952582Z Lee's Pharm picks up 1cBio's preclinical PARP1 inhibitor for China and SE Asia https://allsci.com/news/research/pla2g2d-anti-pd-1-resistance-independent-research/ AllScien 2026-09-09T17:07:23.605502Z Independent research teams validate Apeximmune's PLA2G2D target for overcoming anti-PD-1 resistance https://allsci.com/news/venture-financing/peptide-drug-conjugate-fda-clearance-twostep/ AllScien 2026-09-09T16:59:27.306886Z Stanford spinout TwoStep raises USD 62.5m as lead peptide-drug conjugate clears FDA IND https://allsci.com/news/regulatory/fda-clearance-ap308-iga-nephropathy-alebund/ AllScien 2026-09-09T16:50:39.374391Z Alebund gains FDA IND clearance for IgA-cleaving AP308 in IgA nephropathy https://allsci.com/news/clinical-trials/darovasertib-uveal-melanoma-trial-ideaya-and/ AllScien 2026-09-09T16:41:42.717868Z IDEAYA, Servier expand darovasertib into Phase III adjuvant uveal melanoma https://allsci.com/news/regulatory/icp-b381-prostate-cancer-innocare-gains-approval/ AllScien 2026-09-09T15:58:47.179791Z InnoCare gains China IND clearance for PSMA/STEAP1 bispecific ADC ICP-B381 https://allsci.com/news/venture-financing/menin-inhibition-diabetes-kura-spins-out-caspian/ AllScien 2026-09-09T15:47:14.976700Z Kura launches Caspian with USD 50m to advance menin inhibition in diabetes https://allsci.com/news/research/lsd-serotonin-receptor-uc-davis-researchers/ AllScien 2026-09-09T15:03:49.300321Z UC Davis researchers map LSD structure to guide non-hallucinogenic drug design https://allsci.com/news/venture-financing/ctla-4-antibody-cancer-hbm-holdings-oncology/ AllScien 2026-09-09T14:14:01.534445Z Harbour Bio partner Solstice raises USD 225m to advance CTLA-4 antibody in neoadjuvant cancer https://allsci.com/news/clinical-trials/rig-101-phase-ii-trial-leyden-labs-advances-into/ AllScien 2026-09-09T12:55:18.743940Z Leyden Labs advances RIG-101 after Phase I shows safety and on-target immune activation https://allsci.com/news/clinical-trials/pra-216-phase-i-results-sustains-dual-pathway/ AllScien 2026-09-09T12:46:54.623834Z Prana reports prolonged Type 2 biomarker suppression with IL-4Rα/TSLP bispecific https://allsci.com/news/clinical-trials/pmb-ct01-car-t-therapy-achieves-complete/ AllScien 2026-09-09T12:42:16.868751Z Lancet data show durable responses with PeproMene's BAFF-R CAR T after CD19 CAR T failure https://allsci.com/news/clinical-trials/deucrictibant-xr-hae-pharvariss-cuts-attack-rate/ AllScien 2026-09-09T12:37:07.178370Z Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy https://allsci.com/news/venture-financing/tectora-therapeutics-series-a-funding-schrodinger/ AllScien 2026-09-09T12:10:07.413332Z Schrödinger spins out Tectora with USD 55m Series A for immunology programs https://allsci.com/news/licensing-and-partnerships/assembly-bio-gilead-hsv-profit-share-converts/ AllScien 2026-09-09T11:25:27.482739Z Assembly Bio converts HSV program from royalty deal to 40% US profit-share with Gilead https://allsci.com/news/clinical-trials/alpha-1-antitrypsin-gene-therapy-beams-base/ AllScien 2026-09-09T09:34:04.038634Z Beam reports durable BEAM-302 AAT restoration, advances pivotal cohort https://allsci.com/news/ipo-public-listing/korsana-ipo-alzheimers-goes-public-with-usd-380m/ AllScien 2026-09-09T09:20:16.811904Z Korsana goes public with USD 380m raise and Alzheimer's antibody poised for Phase I https://allsci.com/news/clinical-trials/evo756-phase-iib-trial-failure-fails-second-in/ AllScien 2026-09-09T08:41:23.493838Z Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss